IN2014DN09445A - - Google Patents

Info

Publication number
IN2014DN09445A
IN2014DN09445A IN9445DEN2014A IN2014DN09445A IN 2014DN09445 A IN2014DN09445 A IN 2014DN09445A IN 9445DEN2014 A IN9445DEN2014 A IN 9445DEN2014A IN 2014DN09445 A IN2014DN09445 A IN 2014DN09445A
Authority
IN
India
Prior art keywords
protein complexes
viral proteins
engineered viral
vaccine
methods
Prior art date
Application number
Inventor
Christopher Patrick Marshall
Original Assignee
Marshall Christophe R Patrick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marshall Christophe R Patrick filed Critical Marshall Christophe R Patrick
Publication of IN2014DN09445A publication Critical patent/IN2014DN09445A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)

Abstract

The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross -links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.
IN9445DEN2014 2012-05-09 2013-05-09 IN2014DN09445A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644830P 2012-05-09 2012-05-09
PCT/US2013/040228 WO2013169961A1 (en) 2012-05-09 2013-05-09 Conformationally specific viral immunogens

Publications (1)

Publication Number Publication Date
IN2014DN09445A true IN2014DN09445A (en) 2015-07-17

Family

ID=49548782

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9445DEN2014 IN2014DN09445A (en) 2012-05-09 2013-05-09

Country Status (7)

Country Link
US (5) US20130302366A1 (en)
EP (2) EP2846828B1 (en)
JP (4) JP2015518819A (en)
AU (5) AU2013259548A1 (en)
CA (1) CA2873048C (en)
IN (1) IN2014DN09445A (en)
WO (1) WO2013169961A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773309T3 (en) 2013-07-25 2020-07-10 Calder Biosciences Inc Conformationally stabilized RSV pre-fusion F proteins
JP6704849B2 (en) 2013-08-03 2020-06-03 アバター・メディカル・エルエルシー Influenza hemagglutinin protein and method thereof
AU2018313000A1 (en) 2017-08-07 2020-02-27 Calder Biosciences Inc. Conformationally stabilized RSV pre-fusion F proteins
US11623004B2 (en) 2018-03-16 2023-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncytial virus infection
AU2021271016A1 (en) * 2020-05-12 2023-01-19 The Regents Of The University Of California SARS-CoV2 neutralizing single domain antibody constructs

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311920B1 (en) * 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
WO2001026681A2 (en) 1999-10-13 2001-04-19 Chiron Corporation Method of obtaining cellular immune responses from proteins
EP1282722B1 (en) 1999-10-15 2011-06-15 Avatar Medical, L.L.C. Stabilized proteins
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7179468B1 (en) * 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
US20060165715A1 (en) 2001-12-17 2006-07-27 Clore Marius G Gp41 inhibitor
US20080206264A1 (en) 2003-02-04 2008-08-28 New York University Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists
ATE532793T1 (en) * 2003-07-03 2011-11-15 Avatar Biotechnologies Inc METHOD FOR PRODUCING MOLECULES WITH REDUCED IMMUNOGENICITY
EP2354153A3 (en) * 2004-06-01 2012-05-30 Merck Sharp & Dohme Corp. Stable peptide mimetic of HIV gp41 fusion intermediate
WO2007149491A2 (en) * 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Soluble stabilized trimeric hiv env proteins and uses thereof
UA103751C2 (en) * 2007-07-27 2013-11-25 Имматикс Биотекнолоджис Гмбх Immunogenic peptide for immunotherapy
AU2008287340A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2009048631A1 (en) * 2007-10-11 2009-04-16 University Of Tennessee Research Foundation PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF
EP2340038B1 (en) * 2008-10-10 2018-01-10 Children's Medical Center Corporation Biochemically stabilized hiv-1 env trimer vaccine
WO2011066221A1 (en) 2009-11-24 2011-06-03 International Aids Vaccine Initiative Immunogen prioritization for vaccine design
US20130236905A1 (en) 2010-05-18 2013-09-12 Christopher Marshall Assay for identifying antigens that activate b cell receptors comprising neutralizing antibodies
WO2013063366A2 (en) * 2011-10-27 2013-05-02 Stc.Unm Methods for screening viral like particles and identifying neutralizing epitopes and related vaccines, constructs, and libraries
EP2804948B1 (en) 2012-01-20 2020-04-15 The Government of The Hong Kong Special Administrative Region of The People's Republic of China A novel paramyxovirus and uses thereof

Also Published As

Publication number Publication date
WO2013169961A1 (en) 2013-11-14
JP2022163180A (en) 2022-10-25
AU2018200502A1 (en) 2018-02-15
JP2015518819A (en) 2015-07-06
US11752191B2 (en) 2023-09-12
AU2013259548A1 (en) 2014-11-27
JP6692853B2 (en) 2020-05-13
US10155023B2 (en) 2018-12-18
EP3483174A1 (en) 2019-05-15
JP2018150330A (en) 2018-09-27
AU2024201200A1 (en) 2024-03-14
AU2019216695A1 (en) 2019-09-05
CA2873048A1 (en) 2013-11-14
EP2846828A4 (en) 2015-07-01
US20130317205A1 (en) 2013-11-28
CA2873048C (en) 2020-10-27
US20130302366A1 (en) 2013-11-14
US20210322512A1 (en) 2021-10-21
EP2846828A1 (en) 2015-03-18
US20190105368A1 (en) 2019-04-11
JP7472209B2 (en) 2024-04-22
JP2020125323A (en) 2020-08-20
AU2021204169A1 (en) 2021-07-15
US20180117116A1 (en) 2018-05-03
EP2846828B1 (en) 2018-11-21
AU2018200502B2 (en) 2019-10-03
AU2021204169B2 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2017014908A (en) Trispecific binding proteins and methods of use.
MX2018009990A (en) Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist.
EA201591287A1 (en) VACCINES CONTAINING STABILIZED TRIMMERS OF THE HUMAN IMMUNODEFICIENCY VIRUS VIRUS, AND METHODS OF THEIR USE
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
MX364689B (en) Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type.
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2015008847A (en) Influenza virus immunogenic compositions and uses thereof.
WO2013054199A3 (en) Cmv antigens and uses thereof
EA202090699A2 (en) COMPOSITIONS CONTAINING A BUFFER, VACCINES THAT CONTAIN COMPOSITIONS CONTAINING A BUFFER, AND THEIR APPLICATION
EA201391515A1 (en) INACTIVATED DENGE VIRUS VACCINE
WO2015052543A3 (en) Malaria vaccination
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
IN2014DN09445A (en)
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2019005102A (en) Synthetic chimeric poxviruses.
MX2017008406A (en) Amino acid and peptide conjugates and uses thereof.
MX2022002635A (en) Angiopoietin-like 4 antibodies and methods of use.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX363149B (en) Influenza nucleoprotein vaccines.
MX2019007924A (en) Influenza vaccines.
WO2016049522A3 (en) Compositions comprising ch505 envelopes, and trimers
WO2015086354A3 (en) Novel promiscuous hpv16-derived t helper epitopes for immunotherapy
MX358507B (en) Chimeric vaccine antigens against hepatitis c virus.